PAVmed Provides Business Update and Preliminary Second Quarter 2022 Financial Results
Lucid’s EsoGuard test volume grows 60% and LucidDx Labs fully operational Veris Health Cancer Care Platform to commercially launch this year Conference call to be held today at 4:30 PM EDT NEW YORK–(BUSINESS WIRE)–$LUCD #LUCD—PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, … [Read more…]
